NEW YORK, April 17, 2008 (PRIME NEWSWIRE) -- Veteran business journalist Sasha Salama joins Hojabr Alimi, Chief Executive Officer, President & Director, Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), to discuss the company's industry, strategy, financials and positioning.
Click here to view video: http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=30774&k=AC93775C20A3CBDF638FBFF18896BEAB
Hojabr Alimi, one of our founders, has served as our chief executive officer, president and director since 1999 and was appointed as chairman of the board of directors in June 2006. Prior to co-founding our company with his spouse in 1999, Mr. Alimi was a corporate microbiologist for Arterial Vascular Engineering. Mr. Alimi received a B.A. in biology from Sonoma State University.
About Oculus Innovative Sciences, Inc.:
Oculus Innovative Sciences, Inc. is a biopharmaceutical company focused on the development, manufacture and marketing of a family of products intended to help prevent and treat infection in acute and chronic wounds. Oculus' platform technology, called Microcyn(r), is a non-irritating shelf-stable solution containing oxychlorine compounds that is designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA), as well as viruses, fungi and spores.
For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.
The NASDAQ CEO Signature Series logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4839